keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
dBET6 是一种基于 PROTAC 的选择性和细胞渗透性 BET 降解剂,IC50值为 14 nM。 它具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 947 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 2,990 | 现货 | ||
50 mg | ¥ 3,970 | 现货 | ||
100 mg | ¥ 5,260 | 现货 | ||
200 mg | ¥ 6,590 | 现货 | ||
500 mg | ¥ 9,780 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,190 | 现货 |
产品描述 | dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity. |
靶点活性 | BET:14 nM |
体外活性 | dBET6 (100 nM) exhibits antitumor activity against T cell acute lymphoblastic leukemia (T-ALL) lines via degradation of BRD4. |
体内活性 | dBET6 (7.5 mg/kg, p.o., BID) decreases the leukemic burden in a disseminated mouse model of T-ALL. |
动物实验 | MOLT4 human T-ALL cells are intravenously injected into NSG mice (2×106 cells/mouse). Luminescence is utilized to monitor engraftment (evident at day 6), at which point mice are randomized into three cohorts that receive dBET6 (7.5 mg/kg BID, n = 8), JQ1 (20 mg/kg QD, n = 9) or vehicle (captisol, n = 9) treatment for 14 days. Survival of all three cohorts is subsequently monitored using hind limb paralysis caused by a high femoral leukemic burden as a defined endpoint. SUPT11 human T-ALL cells (mCherry+ and Luciferase+) are intravenously injected into NSG mice (2.52×106 cells/mouse). Luminescence is used to monitor successful engraftment, occurring 10 days after injection. At this point, animals are randomized into three cohorts that receive dBET6 (7.5 mg/kg BID, n = 7), JQ1 (7.5 mg/kg BID, n = 7) or vehicle (captisol, n = 7) treatment for 18 days. Treatment burden is assessed via total body luminescence imaging as well as by bone marrow infiltration by mCherry+ T-ALL cells. |
分子量 | 841.37 |
分子式 | C42H45ClN8O7S |
CAS No. | 1950634-92-0 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1885 mL | 5.9427 mL | 11.8854 mL | 29.7134 mL |
5 mM | 0.2377 mL | 1.1885 mL | 2.3771 mL | 5.9427 mL | |
10 mM | 0.1189 mL | 0.5943 mL | 1.1885 mL | 2.9713 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
dBET6 1950634-92-0 Apoptosis Chromatin/Epigenetic Epigenetic Reader Domain dBET-6 PROTACs Inhibitor inhibit dBET 6 inhibitor